Despite the long history of bendamustine as treatment for indolent nonHodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39-84), and patients had received a median of 3 prior therapies. The histologies included grades 1-2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14Á1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8Á9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Bendamustine is one of the most commonly used chemotherapy agents for treatment of patients with nonHodgkin lymphoma (NHL). Despite over 50 years of clinical use, including over 30 years of use exclusively in the former German Democratic Republic, there are limited data regarding the long-term toxicity and efficacy of bendamustine or bendamustine-based combinations.
In October 2008, the United States Food and Drug Administration approved bendamustine for treatment of patients with indolent B-cell NHL that progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen. The approval was based on a single-arm phase II trial in which patients with rituximab-refractory indolent and transformed B-cell NHL were treated with bendamustine 120 mg/m 2 on days 1 and 2 every 21 days for up to 8 cycles (Friedberg et al, 2008) . A second trial using the same dosing regimen (SDX-105-03) (Kahl et al, 2010) and a third trial (SDX-105-02) in which patients with relapsed indolent B-cell NHL received bendamustine 90 mg/m 2 on days 1 and 2 plus rituximab 375 mg/m 2 on day 1 every 28 days for up to six cycles were conducted shortly thereafter. In total, 245 patients were treated at 45 sites throughout the United States, Canada and Australia. With a median reported follow-up ranging from 11Á8 to 26 months, the single-agent trials reported a median progression-free survival (PFS) of 7Á1 months (Friedberg et al, 2008) and 9Á7 months (Kahl et al, 2010) , while the combination trial reported a median PFS of 23 months . However, the long-term efficacy in these trials remains unclear. The most common reported toxicities in the three trials included gastrointestinal complaints, fatigue, myelosuppression and infection. Four patients were reported to have developed myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), or chronic myelomonocytic leukaemia; however, due to the limited length of follow-up in each of the studies, it is likely that some bendamustine-related secondary cancers were not captured. Given the widespread use of bendamustine, data on longterm outcomes are essential for patients and clinicians to understand potential risks and benefits of therapy. Moreover, recent data from the GALLIUM study suggesting an increased rate of treatment-related deaths among patients treated with bendamustine plus rituximab or obinutuzumab make long-term follow-up data particularly relevant (Marcus et al, 2016) . We collected and analysed long-term follow-up data from patients treated on the three international phase 2 trials described above with the goal of evaluating long-term efficacy and long-term toxicity with particular attention to second cancers and stem cell collection.
Methods
This was a retrospective cohort study. We contacted all 45 sites where the SDX-105-01, -02 and -03 trials took place.
After obtaining Institutional Review Board approval at each site, we collected patient-level data, including demographics, lymphoma-related information, prior therapies, administration of bendamustine, adverse events with special attention around subsequent malignancies, stem cell collection, subsequent therapies and patient outcomes. Patients surviving beyond the defined follow-up period of the original studies were followed at the discretion of the treating physician. Our objectives were to describe the toxicity profile of bendamustine and bendamustine plus rituximab in patients with previously treated NHL; and to estimate the rates of secondary malignancies, successful haematopoietic stem cell collection, response to subsequent treatment regimens, as well as time to next treatment, event-free survival (EFS) and overall survival (OS) in these patients. EFS was defined as the time from start of bendamustine until progression, start of next therapy or death from any cause.
Descriptive statistics were used to estimate the frequency, severity and duration of all treatment-related toxicities, second cancers, rate of successful stem cell collection and response to subsequent therapies. Median follow-up was calculated using the reverse Kaplan-Meier method. The period of interest for treatment-related toxicities included the time between date of start of bendamustine and date of subsequent treatment. The period of interest for second cancers included the time between date of start of bendamustine and the last date of follow-up or death/treatment. The KaplanMeier method was used to estimate time-to-event statistics, including the median survival time, survival rate and incidence rate of MDS/AML at a particular time. In addition, cumulative incidence rates were estimated by treating death from any cause as the competing risk event.
Results
Investigators at 21 of 45 trial-participating sites contacted agreed to participate, providing data for 149 out of the 245 subjects that participated in the SDX-105-01, -02 and -03 trials. Patient characteristics are described in Table I .
Patients treated with single-agent bendamustine (n = 106) received a median of 6 cycles (range 1-8 cycles) at a median cycle duration of 23 days (intended cycle duration was 21 days). Reasons for receiving fewer than the planned number of cycles included toxicity (n = 27), progression (n = 16) and other (n = 6). Patients treated with bendamustine and rituximab (n = 43) received a median of 6 cycles, with an average cycle length of 35 days (intended cycle duration was 28 days). Of the 15 subjects who received fewer than the planned number of cycles, 5 stopped due to toxicity and 3 stopped due to progression.
With a median follow-up of 8Á9 years [95% confidence interval (CI) 8Á7-9Á4] after study entry, 23 patients developed 25 cancers following bendamustine. Six patients developed MDS and 2 more developed AML, resulting in an annual incidence rate of 0Á5%/person/year, and a cumulative incidence rate of 6Á2% (95% CI 3Á1-12Á2%) at the end of maximum follow-up date, adjusting for death from any cause as a competing event. The median time to MDS/AML among subjects that developed MDS/AML following bendamustine was 23 months (range 10-103). The median time to MDS/ AML from the date of diagnosis was 89 months (range 33-226). One of the patients had a prior myeloid neoplasm and one had a prior germ cell tumour. Patients who developed MDS/AML had received a median of 5 therapies, including bendamustine, before developing the myeloid malignancy, which is the same as the median number of therapies received by the entire cohort. In univariate analysis, age at lymphoma diagnosis (P = 0Á44), lymphoma histology, total number of systemic regimens (P = 0Á44) or total dose of bendamustine (P = 0Á29) were associated with MDS/AML. Cytogenetics for each case were not available. Other cancers included non-melanoma skin cancer (n = 6), adenocarcinoma (colon n = 2; prostate n = 2; lung n = 2; breast n = 1), squamous cell neck cancer (n = 1), squamous cell anal cancer (n = 1), hepatocellular carcinoma (n = 1) and bladder cancer (n = 1). None of these occurred in the 12 patients with a history of solid tumour before bendamustine administration.
Twelve patients had stem cell collection attempted following bendamustine, 9 of whom were collected successfully. Seven patients had stem cells collected with granulocyte colony-stimulating factor (GCSF) alone, 1 with GCSF plus chemotherapy, and 1 with GCSF plus plerixafor. The median time to stem cell collection attempt was 12Á5 months (range 1-96 months), with unsuccessful collections occurring at 3, 32 and 96 months. All but two patients, including one with an unsuccessful collection, had received other therapies in the interval between stopping bendamustine and attempted stem cell collection. Data regarding post-transplant engraftment were not available. Following the completion of bendamustine and before inititiation of subsequent therapy, 26 infections were reported. The most common infections were sinopulmonary (n = 14), followed by herpes simplex virus (HSV)/varicella zoster virus (VZV) (n = 6), sepsis (n = 3) and urinary tract infection (n = 3).
At the time of data collection, 80 patients had experienced disease progression, 98 had undergone subsequent therapy, including 31 patients without reported progression, and 93 had died. The median EFS of the whole group was 14Á1 months (95% CI 10Á0-20Á3; Fig 1) , and the EFS rate at 2 and 5 years was 38Á1% and 19Á8%, respectively. EFS was associated with the number of therapies prior to bendamustine (P < 0Á01) and follicular lymphoma (FL) International Prognostic Index (FLIPI) (for FL only; P = 0Á02), but not histology. The median EFS in the single-agent bendamustine group was 9Á9 months (95% CI 7Á8-11Á9), while the median EFS in the bendamustine-rituximab group was 33Á8 months (95% CI 20Á3-49Á9). Of the 12 patients reported to be event free beyond 8 years, 10 had achieved a complete response (CR) while two were partial responders, 10 had FL while one had marginal zone lymphoma (MZL) and one had small lymphocytic lymphoma (SLL), eight were treated with bendamustine-rituximab and four were treated with singleagent bendamustine.
The median OS after start of bendamustine was 65Á9 months (95% CI 38Á8-91Á6; Fig 2) . OS was associated with FLIPI at start of bendamustine (P = 0Á01) and histology (P = 0Á04; median OS of FL was 84Á9 months, SLL was 79Á0 months, mantle cell lymphoma was 66Á5 months, MZL was 40Á2 months, and transformed lymphoma was 7Á0 months), but not response to last therapy prior to bendamustine or the number of therapies prior to bendamustine. Patients enrolled on the single-agent bendamustine studies had a median OS of 44Á9 months, while the patients enrolled on the bendamustine-rituximab study had a median OS of 113Á2 months (P < 0Á01). The causes of death were lymphoma (n = 47), subsequent treatment toxicity (n = 8), MDS/AML (n = 5), other cancer (n = 2), bendamustine toxicity (n = 2), other (n = 7) and unknown (n = 22).
A total of 98 patients received a median of 2 therapies following bendamustine (range 1-8), with the first treatment occurring a median of 12Á1 months (range 0Á1-112) following the final dose of bendamustine. The reported best response to the first subsequent treatment was CR (n = 12; 12%), partial response (n = 6; 6%), atable disease (n = 19; 19%), progressive disease (n = 13; 13%), unknown/not reported/not evaluable (n = 46; 47%). There was no association between response to bendamustine and response to subsequent treatment.
Discussion
This is the first published study to provide truly long-term evidence of the safety and efficacy of bendamustine and bendamustine-rituximab in patients with previously treated indolent NHL. The strengths of this multicentre, international study include the patient-level data and the duration of follow-up of survivors. No clear new safety signals attributable to bendamustine were identified, nor did we identify a significant impact of bendamustine on stem cell collection or Given that bendamustine induces dose-dependent DNA damage (Beeharry et al, 2012) , we hypothesized that it could be associated with secondary malignancies. We found that roughly 6-11% of patients had developed MDS/AML within the maximum follow-up years after receiving bendamustine by cumulative incidence risk method. Although we found no clear association between dose of bendamustine and risk of MDS/AML, it is worth noting that the 120 mg/m 2 dose used in two of the trials reported here exceeds the more commonly administered 90 mg/m 2 . It is difficult to compare these results to other studies for several reasons. Most studies reporting on rates of second cancers do so after frontline treatment rather than treatment in the relapsed/refractory setting as we report here. Although the average time between start of therapy and the diagnosis of MDS/AML is beyond 5 years, the number of studies that have evaluated the incidence of second cancers beyond 5 years from start of therapy is very small, probably resulting in an underestimation of the true incidence. Similarly, it is not surprising that studies with longer follow-up would find a higher incidence of subsequent cancers simply because patients were observed for a longer time. Among previously treated patients receiving radioimmunotherapy (RIT) with a median follow-up of 4Á4 years, 2Á5% of patients had developed secondary MDS/ AML at an average of 1Á9 years following RIT (Czuczman et al, 2007) , while roughly 10% of previously untreated patients receiving frontline chemotherapy plus RIT developed MDS/AML at 10 years from the start of therapy, with a median time to MDS/AML of 79 months from time of treatment, and with advanced age at start of therapy the primary risk factor associated with the second cancer (Reiss et al, 2015) .
Among 563 patients with indolent NHL enrolled in Gruppo Italiano Studio Linfomi trials, Sacchi et al (2008) reported 12 cases of MDS/AML at a median follow-up of 62 months, with age at first treatment being a significant risk factor for second cancer. Among 526 patients treated on the Southwest Oncology Group S0016 trial with a median follow-up of 9Á6 years from start of therapy, 3% of patients had developed MDS/AML, increased from 1% after 4Á9 years of follow-up (Press et al, 2013; Shadman et al, 2016) . By comparison, the annual population risk of developing MDS or AML in individuals aged over 65 years is roughly 30 per 100 000 and 20 per 100 000 in the United States [Surveillance, Epidemiology, and End Results (SEER) Program, 2016] . Another reason that studies may be difficult to compare is the difference in reporting of rates of secondary cancers. It is possible that we have underestimated the risk of secondary cancers attributable to bendamustine. As we relied on retrospective review of available records, it is possible that some cases of secondary cancers were not captured. While the maximum follow-up of survivors in our series exceeds 10 years, roughly half of all patients had died within 5 years, significantly limiting the number of patients with extended follow-up. To try to compensate for this bias we reported the incidence of MDS/AML as calculated by the cumulative incidence rate method as well as the crude incidence rate. On the other hand, it is possible that our findings overstate the risk of MDS/AML attributable to bendamustine because most patients had received multiple prior lines of chemotherapy. The relatively short average time between bendamustine and diagnosis of MDS/AML supports the possibility that prior treatments were partly responsible for the second cancers. For all of these reasons, it may not be appropriate to extrapolate our findings to the use of bendamustine in the frontline setting. Moreover, some cases of MDS/AML occurred following treatments subsequent to bendamustine, making it still more difficult to define risk attributable to solely to bendamustine in any line of therapy. The ability to successfully collect stem cells may be impacted by prior chemotherapy or radiation therapy, with different chemotherapy agents inducing different degrees of damage to haematopoietic progenitor cells. In a recent phase 3 trial comparing bendamustine plus rituximab (BR) to cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R) in patients with untreated indolent and mantle cell lymphoma, an equal number of patients in each arm underwent successful stem cell collection (Burchardt et al, 2009) . However, the number of patients with attempted stem cell collection was small and none of the patients had received other anti-lymphoma therapies prior to stem cell collection. Nine of 12 patients in our series had a successful stem cell collection, similar to published rates among lymphoma patients in general (Hosing et al, 2009 ) and consistent with the low rate of collection failure following bendamustine in a prospective trial (Chen et al, 2015) , although numbers were small. On going and future studies of bendamustine should attempt, whenever possible, to prospectively address stem cell collection as well as the tolerability of subsequent therapies.
Reporting of additional late onset bendamustine-related toxicities was limited by the initiation of subsequent therapy fairly shortly after cessation of bendamustine in the majority of cases. Notably, sinopulmonary infections and reactivation of HSV/VZV occurred in several patients in the period between bendamustine and the next subsequent therapy. These data suggest that there could be a persistent immune deficit following discontinuation of bendamustine, although it is difficult to determine the degree or duration with the available data.
Our data suggest that a small number of previously treated indolent NHL patients may achieve durable remissions following bendamustine or bendamustine-rituximab.
The published median PFS for single-agent bendamustine was 7Á1 months in one study (Friedberg et al, 2008) and 9Á7 months in the other (Kahl et al, 2010) . The combination of bendamustine plus rituximab resulted in a median PFS of 23 months . In this long-term followup study, we found a median EFS of 9Á9 months for patients receiving bendamustine and 33Á8 months for patients receiving bendamustine plus rituximab, suggesting that the selected bendamustine-only patients were representative of the population enrolled in the earlier studies while the bendamustinerituximab patients may have been a lower risk subgroup of the original study population. Another potential explanation for the difference in outcomes is the under reporting of disease progression that might occur in an observational study. To partially correct for that bias we opted to report EFS, taking into account treatment in the absence of reported progression. Indeed, several patients received subsequent treatment in the absence of reported progression, suggesting that our reported EFS may be an overestimate of the true EFS. Nonetheless, the 10-year EFS of the whole group was about 20%, similar to data with RIT, which has been reported to have a median PFS of less than 1 year but nearly 20% remain in remission at 5 years (Fisher et al, 2005) . It was not surprising that the number of prior therapies was associated with EFS, but no clear variables were associated with durable responses making it hard to identify the subset of patients most likely to benefit. The recently reported GADOLIN study estimated a median PFS of 14Á9 months following bendamustine in patients with rituximab-refractory indolent NHL, suggesting a lower risk cohort than that reported here (Sehn et al, 2016) . Consistent with our results, however, the GADOLIN study demonstrated that OS remains poor in people with rituximab-refractory indolent NHL and new options are clearly needed.
These rigorously collected, patient-level, long-term followup data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for many patients with relapsed or refractory indolent NHL. Similar studies will be required to confirm its safety when administered in the front-line setting.
